| Dr Asad Nasir, MD | |
|
600 Roe Ave Ste 4a, Elmira, NY 14905-1629 | |
| (607) 271-3780 | |
| (607) 271-3894 |
| Full Name | Dr Asad Nasir |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 22 Years |
| Location | 600 Roe Ave Ste 4a, Elmira, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346446721 | NPI | - | NPPES |
| 103053092 | Medicaid | PA | |
| 03781537 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 259212 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Arnot Ogden Medical Center | Elmira, NY | Hospital |
| Schuyler Hospital | Montour falls, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arnot Medical Services Pllc | 0840450748 | 140 |
| Arnot Ogden Medical Center | 5395798417 | 196 |
News Archive
Researchers at Wake Forest University Baptist Medical Center's Institute for Regenerative Medicine demonstrated the generation of a bioengineered human liver organoid using a liver bioscaffold made from an intact liver extracellular matrix, and filled (seeded) with primary human liver progenitor and endothelial cells.
Measuring the biochemical changes in breast tumors with magnetic resonance (MR) spectroscopy enables radiologists to more accurately distinguish benign tumors from cancerous ones, according to a study appearing in the August issue of the journal Radiology.
With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
Zainab Akol, Uganda's AIDS Control Program director, said the health ministry has acquired enough antiretroviral (ARV) drugs to provide treatment for people living with HIV/AIDS until the end of the year, New Vision reports. In addition to 30 tons of drugs, the ministry received at the beginning of August from the Global Fund to Fight AIDS, Tuberculosis and Malaria, it also purchased ARVs worth about $20 million this month, Akol said (Kagolo, 8/27).
› Verified 2 days ago
| Entity Name | Arnot Ogden Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083605661 PECOS PAC ID: 5395798417 Enrollment ID: O20061003000664 |
News Archive
Researchers at Wake Forest University Baptist Medical Center's Institute for Regenerative Medicine demonstrated the generation of a bioengineered human liver organoid using a liver bioscaffold made from an intact liver extracellular matrix, and filled (seeded) with primary human liver progenitor and endothelial cells.
Measuring the biochemical changes in breast tumors with magnetic resonance (MR) spectroscopy enables radiologists to more accurately distinguish benign tumors from cancerous ones, according to a study appearing in the August issue of the journal Radiology.
With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
Zainab Akol, Uganda's AIDS Control Program director, said the health ministry has acquired enough antiretroviral (ARV) drugs to provide treatment for people living with HIV/AIDS until the end of the year, New Vision reports. In addition to 30 tons of drugs, the ministry received at the beginning of August from the Global Fund to Fight AIDS, Tuberculosis and Malaria, it also purchased ARVs worth about $20 million this month, Akol said (Kagolo, 8/27).
› Verified 2 days ago
| Entity Name | Arnot Medical Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427326768 PECOS PAC ID: 0840450748 Enrollment ID: O20120330000383 |
News Archive
Researchers at Wake Forest University Baptist Medical Center's Institute for Regenerative Medicine demonstrated the generation of a bioengineered human liver organoid using a liver bioscaffold made from an intact liver extracellular matrix, and filled (seeded) with primary human liver progenitor and endothelial cells.
Measuring the biochemical changes in breast tumors with magnetic resonance (MR) spectroscopy enables radiologists to more accurately distinguish benign tumors from cancerous ones, according to a study appearing in the August issue of the journal Radiology.
With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
Zainab Akol, Uganda's AIDS Control Program director, said the health ministry has acquired enough antiretroviral (ARV) drugs to provide treatment for people living with HIV/AIDS until the end of the year, New Vision reports. In addition to 30 tons of drugs, the ministry received at the beginning of August from the Global Fund to Fight AIDS, Tuberculosis and Malaria, it also purchased ARVs worth about $20 million this month, Akol said (Kagolo, 8/27).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Asad Nasir, MD 571 Saint Josephs Blvd Fl 2, Elmira, NY 14901-3230 Ph: (607) 271-2050 | Dr Asad Nasir, MD 600 Roe Ave Ste 4a, Elmira, NY 14905-1629 Ph: (607) 271-3780 |
News Archive
Researchers at Wake Forest University Baptist Medical Center's Institute for Regenerative Medicine demonstrated the generation of a bioengineered human liver organoid using a liver bioscaffold made from an intact liver extracellular matrix, and filled (seeded) with primary human liver progenitor and endothelial cells.
Measuring the biochemical changes in breast tumors with magnetic resonance (MR) spectroscopy enables radiologists to more accurately distinguish benign tumors from cancerous ones, according to a study appearing in the August issue of the journal Radiology.
With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
Zainab Akol, Uganda's AIDS Control Program director, said the health ministry has acquired enough antiretroviral (ARV) drugs to provide treatment for people living with HIV/AIDS until the end of the year, New Vision reports. In addition to 30 tons of drugs, the ministry received at the beginning of August from the Global Fund to Fight AIDS, Tuberculosis and Malaria, it also purchased ARVs worth about $20 million this month, Akol said (Kagolo, 8/27).
› Verified 2 days ago
Rohail Aijaz Baig, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-442-1713 | |
Dr. Franck Taghi Tirgari, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-737-7770 Fax: 607-271-3686 | |
Dr. Samir Shah, DO Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-737-4100 | |
Dr. James G. Freeman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Madison Ave, 3rd Floor, Elmira, NY 14901 Phone: 607-734-1581 Fax: 607-734-0972 | |
Dr. Keith W. Parker, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Madison Ave Fl 3, Elmira, NY 14901 Phone: 607-734-1581 Fax: 607-734-0972 | |
Dr. Ethan Levine, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 600 Roe Ave, Elmira, NY 14905 Phone: 607-735-4623 Fax: 607-271-3711 | |
Dr. Samuel Thomas Jennings, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 600 Fitch St, Suite 202 & 203, Elmira, NY 14905 Phone: 607-271-3780 Fax: 607-271-3894 |